BMY Stock Summary and Trading Ideas (Bristol-Myers Squibb Company | NYSE:BMY)

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Bristol-Myers Squibb Company trades on the NYSE stock market under the symbol BMY.

As of July 17, 2026, BMY stock price climbed to $60.74 with 11,400,295 million shares trading.

BMY has a beta of 0.49, meaning it tends to be less sensitive to market movements. BMY has a correlation of 0.05 to the broad based SPY ETF.

BMY has a market cap of $124.02 billion. This is considered a Large Cap stock.

Last quarter Bristol-Myers Squibb Company reported $11 billion in Revenue and $1.58 earnings per share. This beat revenue expectation by $571 million and exceeded earnings estimates by $.15.

In the last 3 years, BMY traded as high as $65.38 and as low as $39.35.

The top ETF exchange traded funds that BMY belongs to (by Net Assets): VTI, SCHD, VOO, IVV, SPY.

BMY has outperformed the market in the last year with a price return of +34.1% while the SPY ETF gained +20.3%. However, in the short term, BMY had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.1% vs +6.2% return in SPY. But in the last 2 weeks, BMY shares have fared better than the market returning +4.5% compared to SPY -0.2%.

BMY support price is $59.23 and resistance is $61.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMY shares will trade within this expected range on the day.